Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026)
Ardelyx (ARDX) reported Non-Current Deffered Revenue of $13.7 million for Q1 2026, up 64.06% on a YoY basis from $8.4 million in Q1 2025, and little changed quarter-over-quarter from $13.7 million in Q4 2025.
Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Ardelyx has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $13.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 64.06% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (up 64.06% YoY), and the FY2025 full-year result was $13.7 million, up 89.42% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $13.7 million, roughly flat from $13.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $13.7 million in Q3 2025, with the low at $7.2 million in Q4 2024.
- Historically, Non-Current Deffered Revenue has averaged $10.7 million across 5 years, with a median of $10.3 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue soared 321.48% — and 2025, when it sank 31.01%.
- Ardelyx's Non-Current Deffered Revenue stood at $9.0 million in 2022, then declined by 4.22% to $8.6 million in 2023, then dropped by 16.34% to $7.2 million in 2024, then soared by 89.42% to $13.7 million in 2025, then changed by 0.0% to $13.7 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $13.7 million (Q1 2026), $13.7 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 13.70 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 12.77 Mn |
| Jun 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 12.10 Mn |
| Dec 31, 2023 | 8.64 Mn |
| Sep 30, 2023 | 10.29 Mn |
| Jun 30, 2023 | 9.24 Mn |
| Mar 31, 2023 | 11.50 Mn |
| Dec 31, 2022 | 9.03 Mn |
| Sep 30, 2022 | 8.56 Mn |
| Jun 30, 2022 | 12.42 Mn |
| Mar 31, 2022 | 8.56 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 2.95 Mn |